阿尔茨海默病与免疫疗法。
Alzheimer's disease and immunotherapy.
机构信息
Department of Medicine, Nassau University Medical Center, East Meadow, NY 11554, USA.
出版信息
Aging Dis. 2013 Mar 6;4(4):210-20. Print 2013 Aug.
Abstract
Alzheimer's disease (AD) is a growing health care epidemic. It is the most common cause of dementia and its incidence is rising. Age, which influences the oxidative and inflammatory states of the brain, is the most important risk factor. Currently there is no disease modifying treatments available for this irreversible, progressive debilitating disease. Immunotherapy represents an emerging, potentially disease modifying strategy aimed at reducing the pathological lesions of AD and facilitating cognitive improvement. Many clinical trials are currently underway. This literature review highlights current knowledge regarding the physiology of aging and how it relates to the pathogenesis of AD. In addition, immunotherapy is discussed in the context of its mechanism, current studies and future goals.
摘要
阿尔茨海默病（AD）是一种日益严重的健康危机。它是痴呆症的最常见病因，其发病率正在上升。年龄是影响大脑氧化和炎症状态的最重要危险因素。目前，对于这种不可逆转、进行性衰弱的疾病，尚无有效的治疗方法。免疫疗法是一种新兴的、有潜力的疾病修饰策略，旨在减少 AD 的病理损伤并促进认知改善。目前有许多临床试验正在进行。本文综述了关于衰老生理学及其与 AD 发病机制关系的现有知识。此外，还讨论了免疫疗法的作用机制、当前研究和未来目标。
相似文献
1
Alzheimer's disease and immunotherapy.阿尔茨海默病与免疫疗法。
Aging Dis. 2013 Mar 6;4(4):210-20. Print 2013 Aug.
3
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.阿尔茨海默病治疗的新策略：抗淀粉样β单克隆抗体概述
Indian J Pharmacol. 2016 Nov-Dec;48(6):629-636. doi: 10.4103/0253-7613.194867.
4
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.β淀粉样蛋白 DNA 疫苗接种治疗阿尔茨海默病：关注疾病预防。
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. doi: 10.2174/187152710791012080.
5
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
6
Amyloid-beta immunotherapy for Alzheimer's disease.阿尔茨海默病的淀粉样β免疫疗法。
CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017.
7
Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium.使用微剂量锂盐减缓唐氏综合征患者阿尔茨海默病的进展
Med Hypotheses. 2020 Apr;137:109573. doi: 10.1016/j.mehy.2020.109573. Epub 2020 Jan 20.
8
Drugs in Alzheimer's disease Dementia: An overview of current pharmacological management and future directions.治疗阿尔茨海默病性痴呆的药物：当前药物治疗管理概述及未来方向
Psychiatr Danub. 2016 Sep;28(Suppl-1):136-140.
9
Amyloid beta peptide immunotherapy in Alzheimer disease.阿尔茨海默病中的β淀粉样肽免疫疗法。
Rev Neurol (Paris). 2014 Dec;170(12):739-48. doi: 10.1016/j.neurol.2014.10.003. Epub 2014 Nov 6.
10
Treatment of Alzheimer's disease: current status and new perspectives.阿尔茨海默病的治疗：现状与新视角
Lancet Neurol. 2003 Sep;2(9):539-47. doi: 10.1016/s1474-4422(03)00502-7.
引用本文的文献
1
Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review.阿尔茨海默病相关分子通路中的遗传变异性：综述
Front Aging Neurosci. 2021 Mar 18;13:646901. doi: 10.3389/fnagi.2021.646901. eCollection 2021.
2
Royal jelly promotes DAF-16-mediated proteostasis to tolerate β-amyloid toxicity in C. elegans model of Alzheimer's disease.蜂王浆促进DAF-16介导的蛋白质稳态，以耐受阿尔茨海默病秀丽隐杆线虫模型中的β-淀粉样蛋白毒性。
Oncotarget. 2016 Aug 23;7(34):54183-54193. doi: 10.18632/oncotarget.10857.
3
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.两项3期扩展研究中bapineuzumab在阿尔茨海默病患者中的长期安全性和耐受性
Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.
4
Construction of AAV-rat-IL4 and Evaluation of its Modulating Effect on Aβ (1-42)-Induced Proinflammatory Cytokines in Primary Microglia and the B92 Cell Line by Quantitative PCR Assay.AAV-大鼠-IL4的构建及其通过定量PCR检测对原代小胶质细胞和B92细胞系中Aβ(1-42)诱导的促炎细胞因子的调节作用评估
Jundishapur J Microbiol. 2016 Mar 5;9(3):e30444. doi: 10.5812/jjm.30444. eCollection 2016 Mar.
5
Cranberry Extract Standardized for Proanthocyanidins Alleviates β-Amyloid Peptide Toxicity by Improving Proteostasis Through HSF-1 in Caenorhabditis elegans Model of Alzheimer's Disease.原花青素标准化的蔓越莓提取物通过在秀丽隐杆线虫阿尔茨海默病模型中通过HSF-1改善蛋白质稳态来减轻β-淀粉样肽毒性。
J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1564-1573. doi: 10.1093/gerona/glv165. Epub 2015 Sep 23.
6
Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.抗人α-突触核蛋白N端肽抗体可保护多巴胺能细胞免于死亡，并改善帕金森病AAV-α-突触核蛋白大鼠模型中的行为缺陷。
PLoS One. 2015 Feb 6;10(2):e0116841. doi: 10.1371/journal.pone.0116841. eCollection 2015.
7
Novel immunological approaches for the treatment of Alzheimer's disease.治疗阿尔茨海默病的新型免疫疗法
Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi. 2014;14(3):139-151. doi: 10.3969/j.issn.1672-6731.2014.03.001.
8
Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease.轻度认知障碍或阿尔茨海默病患者海马体积与认知表现的相关性
CNS Neurosci Ther. 2015 Jan;21(1):15-22. doi: 10.1111/cns.12317. Epub 2014 Aug 21.
9
Etiology and pathogenesis of late-onset Alzheimer's disease.晚发性阿尔茨海默病的病因和发病机制。
Curr Allergy Asthma Rep. 2014 Mar;14(3):417. doi: 10.1007/s11882-013-0417-1.
10
Immunotherapy for Alzheimer's disease.阿尔茨海默病的免疫疗法。
Biochem Pharmacol. 2014 Apr 15;88(4):499-507. doi: 10.1016/j.bcp.2013.12.020. Epub 2014 Jan 9.
本文引用的文献
1
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.在兔子中对基于 DNA 的阿尔茨海默病表位疫苗进行改良。
Hum Vaccin Immunother. 2013 May;9(5):1002-10. doi: 10.4161/hv.23875. Epub 2013 Feb 11.
2
Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.单剂量静脉注射泊奈单抗在轻至中度阿尔茨海默病患者中的安全性和药理学：一项I期随机、安慰剂对照、双盲、剂量递增研究。
Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b.
3
Cell and gene therapy in Alzheimer's disease.阿尔茨海默病的细胞和基因治疗。
Stem Cells Dev. 2013 May 15;22(10):1490-6. doi: 10.1089/scd.2012.0633. Epub 2013 Mar 4.
4
Complement gene single nucleotide polymorphisms and biomarker endophenotypes of Alzheimer's disease.补体基因单核苷酸多态性与阿尔茨海默病的生物标志物内表型。
J Alzheimers Dis. 2013;35(1):51-7. doi: 10.3233/JAD-121930.
5
Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers.磷脂与阿尔茨海默病：改变、机制及潜在生物标志物
Int J Mol Sci. 2013 Jan 10;14(1):1310-22. doi: 10.3390/ijms14011310.
6
2012: A watershed year for Alzheimer's disease research.2012 年：阿尔茨海默病研究的一个分水岭。
J Nutr Health Aging. 2013 Jan;17(1):51-3. doi: 10.1007/s12603-013-0002-2.
7
Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?阿尔茨海默病的被动免疫疗法：我们学到了什么，又将走向何方？
J Nutr Health Aging. 2013 Jan;17(1):49-50. doi: 10.1007/s12603-013-0001-3.
8
A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.一种针对淀粉样斑块的抗体可清除阿尔茨海默病小鼠体内的现有β-淀粉样斑块。
Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.
9
Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.阿尔茨海默病乙酰胆碱酯酶抑制剂和美金刚有效性和成本效益的证据演变：系统评价和经济模型。
Age Ageing. 2013 Jan;42(1):14-20. doi: 10.1093/ageing/afs165. Epub 2012 Nov 22.
10
Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.白细胞介素受体相关激酶 4 信号缺失可抑制阿尔茨海默病小鼠模型中的淀粉样蛋白病理，并改变小胶质细胞表型。
J Neurosci. 2012 Oct 24;32(43):15112-23. doi: 10.1523/JNEUROSCI.1729-12.2012.
Zotero 插件